Literature DB >> 21901380

Do we have to withdraw antiandrogenic therapy in prostate cancer patients before PET/CT with [11C]choline?

Giampiero Giovacchini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21901380     DOI： 10.1007/s00259-011-1926-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  26 in total

1.  PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.

Authors:  Giampiero Giovacchini; Maria Picchio; Vincenzo Scattoni; Rita Garcia Parra; Alberto Briganti; Luigi Gianolli; Francesco Montorsi; Cristina Messa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-20       Impact factor: 9.236

2.  Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging.

Authors:  U G Mueller-Lisse; M G Swanson; D B Vigneron; H Hricak; A Bessette; R G Males; P J Wood; S Noworolski; S J Nelson; I Barken; P R Carroll; J Kurhanewicz
Journal:  Magn Reson Med       Date:  2001-07       Impact factor: 4.668

3.  The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration.

Authors:  Michael Souvatzoglou; Gregor Weirich; Sarah Schwarzenboeck; Tobias Maurer; Tibor Schuster; Ralph Alexander Bundschuh; Matthias Eiber; Ken Herrmann; Hubert Kuebler; Hans Juergen Wester; Heinz Hoefler; Juergen Gschwend; Markus Schwaiger; Uwe Treiber; Bernd Joachim Krause
Journal:  Clin Cancer Res       Date:  2011-04-14       Impact factor: 12.531

4.  Effects of endocrine therapy on the primary lesion in patients with prostate carcinoma as evaluated by endorectal magnetic resonance imaging.

Authors:  J Nakashima; Y Imai; M Tachibana; S Baba; K Hiramatsu; M Murai
Journal:  Cancer       Date:  1997-07-15       Impact factor: 6.860

5.  In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer.

Authors:  Anthonius J Breeuwsma; Jan Pruim; Maud M Jongen; Albert J Suurmeijer; Wim Vaalburg; Rien J Nijman; Igle J de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-12       Impact factor: 9.236

6.  Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.

Authors:  T R DeGrado; R E Coleman; S Wang; S W Baldwin; M D Orr; C N Robertson; T J Polascik; D T Price
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

7.  Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells.

Authors:  Toshihiko Hara; Aditya Bansal; Timothy R DeGrado
Journal:  Nucl Med Biol       Date:  2006-10-04       Impact factor: 2.408

8.  The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

Authors:  B J Krause; M Souvatzoglou; M Tuncel; K Herrmann; A K Buck; C Praus; T Schuster; H Geinitz; U Treiber; M Schwaiger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-22       Impact factor: 9.236

9.  11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer.

Authors:  I J de Jong; J Pruim; P H Elsinga; W Vaalburg; H J A Mensink
Journal:  Eur Urol       Date:  2003-07       Impact factor: 20.096

10.  [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

Authors:  Marino Cimitan; Roberto Bortolus; Sandro Morassut; Vincenzo Canzonieri; Antonio Garbeglio; Tanja Baresic; Eugenio Borsatti; Annalisa Drigo; Mauro G Trovò
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-25       Impact factor: 10.057
View more
  8 in total

Review 1.  PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.

Authors:  Giampiero Giovacchini; Elisabetta Giovannini; Rossella Leoncini; Mattia Riondato; Andrea Ciarmiello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

2.  Effect of androgen deprivation therapy on intraprostatic tumour volume identified on 18F choline PET/CT for prostate dose painting radiotherapy.

Authors:  Joachim Chan; Antony Carver; John N H Brunt; Sobhan Vinjamuri; Isabel Syndikus
Journal:  Br J Radiol       Date:  2016-12-20       Impact factor: 3.039

3.  Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?

Authors:  Sotirios Chondrogiannis; Maria Cristina Marzola; Alice Ferretti; Gaia Grassetto; Anna Margherita Maffione; Lucia Rampin; Stefano Fanti; Francesco Giammarile; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-25       Impact factor: 9.236

Review 4.  Functional imaging for prostate cancer: therapeutic implications.

Authors:  Carina Mari Aparici; Youngho Seo
Journal:  Semin Nucl Med       Date:  2012-09       Impact factor: 4.446

5.  The relationship between local recurrences and distant metastases in prostate cancer: can 11C-choline PET/CT contribute to understand the link?

Authors:  Giampiero Giovacchini; Andrea Ciarmiello; Elisabetta Giovannini; Andrei Fodor; Cesare Cozzarini; Paola Mapelli; Elena Incerti; Nadia Di Muzio; Luigi Gianolli; Maria Picchio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-16       Impact factor: 9.236

6.  Diagnostic performance of 18F-fluciclovine PET/CT in prostate cancer patients with rising PSA level ≤ 0.5 ng/ml after multiple treatment failures.

Authors:  Ajalaya Teyateeti; Achiraya Teyateeti; Gregory C Ravizzini; Guofan Xu; Chad Tang; Shi-Ming Tu; Homer A Macapinlac; Yang Lu
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-04-15

7.  Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer.

Authors:  Tore Bach-Gansmo; Katrine Korsan; Trond Velde Bogsrud
Journal:  Tomography       Date:  2022-06-03

8.  Prostate-specific antigen and prostate-specific antigen velocity as threshold indicators in 11C-acetate PET/CTAC scanning for prostate cancer recurrence.

Authors:  Reginald W Dusing; Warner Peng; Sue-Min Lai; Gordon L Grado; Jeffrey M Holzbeierlein; J Brantley Thrasher; Jacqueline Hill; Peter J Van Veldhuizen
Journal:  Clin Nucl Med       Date:  2014-09       Impact factor: 7.794
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.